Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients with Low Bone Mass (original) (raw)

Severe Symptomatic Hypocalcemia after Denosumab Administration in an End-Stage Renal Disease Patient on Peritoneal Dialysis with Controlled Secondary Hyperparathyroidism

Mihály Tapolyai

British Journal of Medicine and Medical Research, 2013

View PDFchevron_right

Denosumab for Osteoporosis in Patients With Primary Hyperparathyroidism and Renal Insufficiency

Zhanna Belaya

Research Square (Research Square), 2022

View PDFchevron_right

Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis

Ambrish Mithal

Frontiers in Endocrinology, 2023

View PDFchevron_right

Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism

Maria Moyses

Nephrology Dialysis Transplantation, 2003

View PDFchevron_right

Comparison between Calcitriol and Calcitriol Plus Low-Dose Cinacalcet for the Treatment of Moderate to Severe Secondary Hyperparathyroidism in Chronic Dialysis Patients

chien-te lee

Nutrients, 2013

View PDFchevron_right

Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients

Diego Brancaccio

Kidney International, 1992

View PDFchevron_right

Treatment of Secondary Hyperparathyroidism in Maintenance Hemodialysis Patients by Intravenous Calcitriol

aquiles jara

Seminars in Dialysis, 1994

View PDFchevron_right

Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism

Daniele Marcelli

American Journal of Kidney Diseases, 1996

View PDFchevron_right

Beneficial role of intravenous calcitriol on bone mineral density in children with severe secondary hyperparathyroidism

Ali Duzova

International Urology and Nephrology, 2000

View PDFchevron_right

Changes in bone turnover after parathyroidectomy in dialysis patients: role of calcitriol administration

Francesco Zaraca

Nephrology Dialysis Transplantation, 2000

View PDFchevron_right

Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy

Jorge Ramirez

Kidney International, 1994

View PDFchevron_right

D. Brancaccio, M. Cozzolino, G. Cannella, P. Messa, M. Bonomimi, G. Cancarini, MR. Caruso, C. Cascone, AM Costanzo, M. Salvadori; FARO Study Group Secondary Hyperparathyroidism in Chronic Dialysis Patients: Results of the Italian FARO Survey on Treatment and Mortality. Blood Purif. 32: 124-32, 2011

Diego Brancaccio

Blood Purification

View PDFchevron_right

Nephrology picture: bone loss due to absence of adequate therapy for severe secondary hyperparathyroidism

Rosilene Elias

Journal of Nephrology, 2022

View PDFchevron_right

Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature

Vladimir Palicka

Acta medica (Hradec Králové) / Universitas Carolina, Facultas Medica Hradec Králové, 2014

View PDFchevron_right

Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases

Soo Min Jang

Pharmacy, 2020

View PDFchevron_right

A Slight Decrease in Renal Function Further Impairs Bone Mineral Density in Primary Hyperparathyroidism

A. Piovesan

The Journal of Clinical Endocrinology & Metabolism, 2006

View PDFchevron_right

Usefulness and pharmacokinetics of subcutaneous calcitriol in the treatment of secondary hyperparathyroidism

Jose Vicente Torregrosa

Nephrology Dialysis Transplantation, 1996

View PDFchevron_right

Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol

Giuseppe Cannella

Kidney International, 1994

View PDFchevron_right

Hyperparathyroidism in the hemodialysis population: A survey of 612 patients

Mahmoud Salem

American Journal of Kidney Diseases, 1997

View PDFchevron_right

Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure

Yusuke Tsukamoto

American Journal of Kidney Diseases, 1995

View PDFchevron_right

Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

Martin Wilkie

Drugs, 2016

View PDFchevron_right

Treatment of Secondary Hyperparathyroidism With Low Dose Intermittent Calcitriol in Hemodialysis Patients

Domenico Laganà

ASAIO Journal, 1995

View PDFchevron_right

Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

Emanuel Zitt

American Journal of Nephrology, 2003

View PDFchevron_right

Management of Secondary Hyperparathyroidism in Hemodialysis Patients

Ulrich Neyer

InTech eBooks, 2011

View PDFchevron_right

The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism

Jose Hervás

American Journal of Kidney Diseases, 1995

View PDFchevron_right